All Content Outsourced Pharma

  1. SK pharmteco Capacity Update April 2025: Cell & Gene Therapy 4/24/2025

    Our integrated expertise — from plasmid science to viral vector and cell therapy manufacturing — can accelerate and de-risk the development of your advanced therapies.

  2. Advancing Cell & Gene Therapies To Patients 4/24/2025

    Discover how we apply our expertise and know-how to efficiently advance your viral vector-based therapeutic through any phase, while enhancing quality and de-risking production.

  3. Tyber, Intech & Resolve Finalize Merger To Form Global CDMO+ For Musculoskeletal Device Solutions 4/24/2025

    In a pivotal move shaping the future of MedTech, Tyber Medical, Intech, and Resolve Surgical Technologies have merged into a unified, leading developer, designer and manufacturer of surgical devices focused on serving the needs of MedTech OEMs and patients.

  4. Pentixapharm Signs Contract Manufacturing Agreement For Yttrium-90-Based PentixaTher With Eckert & Ziegler SE 4/24/2025

    Pentixapharm, a clinical-stage biopharmaceutical company, today announced the signing of a manufacturing agreement with Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE. Under the terms of the agreement, EZR will produce and distribute patient-specific doses of Y90-PentixaTher, Pentixapharm’s lead CXCR4-targeting radiotherapeutic, for use in clinical trials.

  5. Evotec Announces Significant Progress In Strategic Protein Degradation Collaboration With Bristol Myers Squibb 4/24/2025

    Evotec SE today announced further significant progress of the Company’s strategic research collaboration with Bristol Myers Squibb relating to building a high value molecular glue-based pipeline for unmet medical needs.

  6. ITM And Alpha-9 Oncology Enter Into Supply Agreement For Therapeutic Medical Radioisotope Actinium-225 4/24/2025

    ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9), a clinical-stage biotechnology company advancing a distinctive portfolio of differentiated and highly targeted radiopharmaceuticals, today announced the signing of a supply agreement for Actinium-225 (Ac-225) to support the development of Alpha-9’s radiopharmaceutical programs.

  7. ICH Revises Q1 Guideline, Advancing Stability Testing Standards 4/24/2025

    In April 2025, the International Council for Harmonisation (ICH) released draft ICH Q1: Stability Testing of Drug Substances and Drug Products for public consultation. This new draft guideline represents the first major overhaul of global stability testing standards in over two decades.

  8. Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs 4/23/2025

    Discover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.

  9. Tariffs Won't Stop Drug-Candidate Licensing From China Biotechs 4/23/2025

    According to Global Data, the total deal value of U.S. licensing of innovator drug candidates from Chinese biopharma companies has surged since 2020. This is an area way upstream of the current tariff focus on manufacturing. But how this R&D trend and those tariffs play out will  impact your U.S.-based CDMOs.

  10. Process Analytical Technology In The ADC Bioconjugation Process 4/23/2025

    Integrating Process Analytical Technology into validated GMP processes is complex and costly, which requires thorough validation of equipment and cleaning methods. Explore more about PAT's role in ADC production.